Emergent BioSolutions Inc.

EBS • Biotechnology

$6.27

— 0.00 (0.00%)

EarningsLatest report: Jun 30, 2026

FAVORABLE PROFILEAttractiveConfidence: 70%

Quantitative profile — not an investment recommendation.

Quantitative profile — not an investment recommendation.Methodology

Analysis thesis: Solid company profile with reasonable valuation support. The data suggests a balanced quality/value setup.

Market Cap

$323.53M

Growth

7.5%

Cash Flow

3/5

Trend

Mostly stable

Evidence

Positive free cash flow · 2.93Reasonable earnings multiple · 12.57Healthy liquidity · 5.01

Financial data as of: Jun 30, 2026, 12:00 AM UTCLast earnings update: Jun 30, 2026, 12:00 AM UTCLast profile update: Aug 7, 2026, 1:28 PM UTC

Company Snapshot

Key valuation, quality, financial strength, momentum and analyst data.

Price$6.27

Change0.00%

Shares Out51.60M

Market Cap$323.53M

Enterprise Value$765.63M

52W Range5.06 - 14.06

Beta2.34

P/E-1.83

P/S0.42

P/B0.95

P/FCF23.79

EV/Sales0.99

Price$6.27

Change0.00%

Shares Out51.60M

Market Cap$323.53M

Enterprise Value$765.63M

52W Range5.06 - 14.06

Beta2.34

P/E-1.83

P/S0.42

P/B0.95

P/FCF23.79

EV/Sales0.99

EV/EBITDA-53.92

EV/FCF56.30

Earnings Yield-54.65%

FCF Yield4.20%

Dividend Yield0.00%

Gross Margin47.19%

Oper. Margin14.83%

Profit Margin7.08%

Debt/Eq1.09

Current Ratio5.01

Quick Ratio2.41

Revenue 5Y7.49%

FCF 5Y-2.36%

Target$10.00

Target Upside59.49%

Target Median$10.00

Target Range10.00 - 10.00

Volume4.25M

Avg Volume818.38K

EPS Surprise0.46

Investment DNA

How strong this company looks for long-term investors

out of 100

Business Quality

Margins, moat, returns

61/100

Financial Strength

Debt, cash, stability

68/100

Growth Potential

Revenue and expansion

58/100

Price Attractiveness

Cheap or expensive today

92/100

Why this score▼

Positive free cash flow · 2.93Reasonable earnings multiple · 12.57Healthy liquidity · 5.01

Analyst view

Analyst sentiment and price target

EBS

Analyst sentiment

Based on 15 analyst votes · 2026-09-04

83/100

Bullish

Hold

Bearish

Price Target

2026-08-07

Low

$12.00

Mean

$12.00

Median

$12.00

High

$12.00

Company Overview

IPO: 11/15/2006

Industry: Biotechnology

P/B i: 0.95

Debt / Equity i: 1.09

Operating Margin: 14.83%

Net Margin: 7.08%

ROE i: -

ROIC: -

Financial Health

Score14 / 20

Debt / Equity: 1.09

Current Ratio: 5.01

Quick Ratio: 2.41

Status: Good

Insider Transactions

Recent executive and insider activity

Williams Paul Anthony

Transaction: 07/01/2026

SELL

Change

-3,000

Price

$8.40

Filing

07/02/2026

Type

SELL

Hartzel William

Transaction: 06/08/2026

SELL

Change

-1,741

Price

$8.00

Filing

06/10/2026

Type

SELL

Glessner Coleen

Transaction: 06/08/2026

SELL

Change

-2,018

Price

$8.00

Filing

06/10/2026

Type

SELL

Insider	Type	Change	Price	Transaction	Filing
Williams Paul Anthony	SELL	-3,000	$8.40	07/01/2026	07/02/2026
Hartzel William	SELL	-1,741	$8.00	06/08/2026	06/10/2026
Glessner Coleen	SELL	-2,018	$8.00	06/08/2026	06/10/2026
LINDAHL RICHARD S	SELL	-3,964	$8.00	06/08/2026	06/10/2026
Williams Paul Anthony	SELL	-694	$8.00	06/08/2026	06/10/2026
Zoon Kathryn C	SELL	-1,057	$8.97	05/01/2026	05/04/2026
DeGolyer Donald W	SELL	-954	$8.96	05/01/2026	05/04/2026
Dayal Sujata Tyagi	SELL	-980	$8.94	05/01/2026	05/04/2026
Harsanyi Zsolt	BUY	+11,296	$7.99	04/30/2026	05/04/2026
Harsanyi Zsolt	BUY	+25,344	Not reported	04/30/2026	05/04/2026
Fowler Neal Franklin	BUY	+11,296	$7.99	04/30/2026	05/04/2026
Fowler Neal Franklin	BUY	+25,344	Not reported	04/30/2026	05/04/2026
Zoon Kathryn C	BUY	+11,296	$7.99	04/30/2026	05/04/2026
Zoon Kathryn C	BUY	+25,344	Not reported	04/30/2026	05/04/2026
Richard Ronald	BUY	+11,296	$7.99	04/30/2026	05/04/2026
Richard Ronald	BUY	+25,344	Not reported	04/30/2026	05/04/2026
FOWLER JOHN D JR	BUY	+11,296	$7.99	04/30/2026	05/04/2026
FOWLER JOHN D JR	BUY	+25,344	Not reported	04/30/2026	05/04/2026
White Marvin L	BUY	+11,296	$7.99	04/30/2026	05/04/2026
White Marvin L	BUY	+25,344	Not reported	04/30/2026	05/04/2026

About the Company

Emergent BioSolutions Inc.

Emergent BioSolutions Inc. is a life sciences company dedicated to providing vital preparedness and response solutions for a wide range of public health threats (PHTs) across the United States. These threats encompass accidental, deliberate, and naturally occurring events, including chemical, biological, radiological, nuclear, and explosives (CBRNE) incidents, emerging infectious diseases, travel-related health risks, and acute emergency care situations. The company's current product portfolio features essential vaccines and treatments such as BioThrax for anthrax and ACAM2000 for smallpox. It also offers Botulism Antitoxin Heptavalent, vaccinia immune globulin intravenous to manage smallpox vaccine complications, and inhalational anthrax therapies like raxibacumab and Anthrasil. Other key offerings include reactive skin decontamination lotion kits, the Trobigard combination drug-device auto-injector, NARCAN nasal spray for emergency opioid overdose reversal, Vivotif, an oral typhoid fever vaccine, and Vaxchora, a single-dose oral cholera vaccine. Emergent is also actively engaged in developing a robust pipeline of future solutions. This includes AP003 (a multidose naloxone nasal spray), AP007 (a sustained-release nalmefene injection for opioid use disorder), AV7909 (an anthrax vaccine), CGRD-001 (a pralidoxime chloride/atropine auto-injector), CHIKV VLP (a chikungunya virus vaccine), COVID-HIG (for SARS-CoV2 treatment), EGRD-001 (a diazepam auto-injector), SIAN (a cyanide poisoning antidote), and UniFlu (a universal influenza vaccine). Furthermore, the company extends its expertise through comprehensive contract development and manufacturing services (CDMO). These services cover drug substance and product manufacturing, packaging, along with technology transfer and advanced process and analytical development. Emergent BioSolutions Inc., founded in 1998, is headquartered in Gaithersburg, Maryland.

Source - link

Peers

AQST CMPS CRVS ESPR OLMA ORGO PRTA RIGL SIGA SNDL

Size reflects market cap · color matches the chart line

1Y peer performance

Top performers + selected company

Latest news

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Emergent BioSolutions Inc. - EBS

NEW YORK, Sept. 3, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Emergent BioSolutions Inc. ("Emergent" or the "Company") (NYSE: EBS).

PRNewsWire

Emergent BioSolutions Completes Repurchase of $75 Million Aggregate Principal Amount of Senior Unsecured Notes

GAITHERSBURG, Md., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that it has completed the repurchase of $75 million aggregate principal amount of its 3.875% Senior Unsecured Notes due 2028 (the “Senior Unsecured Notes”), following authorization granted by its Board of Directors. In total, Emergent deployed approximately $68 million of cash for the repurchases, resulting in an average repurchase price of 90.6% of face value. Following completion of the repurchases, the outstanding aggregate principal balance of the Senior Unsecured Notes has been reduced to approximately $364.7 million.

GlobeNewsWire

BlackRock Inc. Invests $39.52 Million in Emergent Biosolutions Inc. $EBS

BlackRock Inc. bought a new stake in Emergent Biosolutions Inc. (NYSE: EBS) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 4,716,599 shares of the biopharmaceutical company's stock, valued at approximately $39,525,000. BlackRock Inc. owned approximately 9.14% of Emergent Biosolutions

Defense World

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Emergent BioSolutions Inc. - EBS

NEW YORK, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Emergent BioSolutions Inc. (“Emergent” or the “Company”) (NYSE: EBS).

GlobeNewsWire

Emergent BioSolutions Awarded Contract Modification Valued at Approximately $24 Million for CYFENDUS® (Anthrax Vaccine Adsorbed, Adjuvanted)

GAITHERSBURG, Md., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced a contract modification valued at approximately $24 million from the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS), to supply CYFENDUS® (Anthrax Vaccine Adsorbed, Adjuvanted) for anthrax preparedness efforts. Anthrax remains a significant global biological threat due to its potential use in a bioterrorism event and its implications for public health and national security.

GlobeNewsWire

Earnings Surprises

Period	Estimate	Actual	Surprise
2026-04-30	-0.25	0.21	0.46
2026-02-26	0.11	-0.43	-0.54
2025-10-29	-0.12	1.06	1.18
2025-08-06	-0.26	0.16	0.42
2025-05-07	0.49	0.71	0.22
2025-03-03	-0.35	0.05	0.4
2024-11-06	0.49	1.37	0.88
2024-08-06	-0.97	-2.32	-1.35
2024-05-01	-0.86	0.59	1.45
2024-03-06	-0.33	-0.77	-0.44
2023-11-08	-0.22	-1.44	-1.22
2023-08-08	-0.98	-1.06	-0.08